secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002799
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics: 2025 preliminary revenue ~$823M, Sephience $112M; 2026 guidance $700-800M product revenue
--------------------------------------------------------------------------------

- Preliminary 2025 total product & royalty revenue ~$823.4M, exceeding prior guidance; product revenue ~$587.8M.
- Sephience (sepiapterin) net revenue $112.1M since launch, Q4 alone $92.5M; 946 patients on commercial therapy as of Dec 31.
- Closed sale of remaining Evrysdi royalty to Royalty Pharma for $240M upfront plus up to $60M milestones; retains $150M milestone.
- 2026 guidance: product revenue $700-800M (19-36% YoY growth); GAAP R&D/SG&A $775-815M, non-GAAP $680-720M.
- End-of-Phase 2 meeting for votoplam HD program; Phase 3 trial to start H1 2026; FDA open to Accelerated Approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926002799/0001104659-26-002799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000110465926002799/tmb-20260112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer